Ask AI
ProCE Banner Activity

Beyond the Podium: Continuing the Q&A on Schizophrenia

Podcast Episodes

In this podcast episode, Dr Jonathan Meyer answers additional questions from learners at our Psychopharmacology Update conference. Questions explore other disease states where psychosis can occur, practical considerations around special populations, tolerability, drug combinations, and the potential future of muscarinic-based therapies. 

Released: January 13, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Bristol Myers Squibb. 

Bristol Myers Squibb

Target Audience

This activity is intended for healthcare professionals caring for patients with schizophrenia including psychiatrists, physicians, nurse practitioners, physician associates, registered nurses, pharmacists, social workers, and psychologists.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify the mechanisms of action and pharmacokinetic profiles of novel and emerging therapeutic agents for schizophrenia, extending beyond traditional antidopaminergic antipsychotics

  • Compare the efficacy and safety data of novel and emerging agents in the treatment of schizophrenia

  • Describe the potential of novel antipsychotic therapies to address unmet needs and transform clinical practice in schizophrenia management

Disclosure

Primary Author

Jonathan M. Meyer, MD, DLFAPA: consultant/advisor/speaker: 4MTx, AbbVie, Alkermes, Autobahn, Axsome, Bristol Myers Squibb, Intra-Cellular/Johnson & Johnson, Luye, Neurocrine, Teva.